BioSpace News Archive

World over, vision care has made some significant advances on the adoption of new population health approaches, especially in developed countries, underpinning the evolution of the vision care market.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that total preliminary unaudited revenue for OpGen in 2021 was approximately $4.3 million, compared to approximately $4.2 million in 2020.

SIGA Technologies, Inc. announced that the European Medicines Agency approved SIGA’s Marketing Authorisation Application for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration in July 2018 under the brand name TPOXX®.

Berkeley Lights, Inc., a leader in digital cell biology, and Aanika Biosciences, a growing biotech start-up using edible microbial tags to improve food safety, announced a strategic partnership that will enable faster identification of outbreak sources, reduce incidents of fresh produce contamination and minimize the impact of food borne illness related recalls.

LA JOLLA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Twist Bioscience to validate its NGS Target Enrichment Solutions, high-quality target enrichment panels either curated or custom, with the G4 sequencing platform. Twist NGS Target Enrichment Solutions provide an optimized workflow and

Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, announced a partnership with Watchmaker Genomics to validate its Watchmaker DNA Library Prep Kits with Fragmentation for the G4 sequencing platform.

Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, announced a partnership with Lexogen to demonstrate the G4 sequencing platform’s compatibility with Lexogen’s products for RNA research, specifically the QuantSeq, CORALL and LUTHOR library preparation kits.

Cognition Therapeutics, Inc. provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.

Galmed Pharmaceuticals Ltd. announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that demonstrated an excellent safety profile and tolerability.

Soligenix, Inc. today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.